Jump to a section
- What the reviewed evidence directly compares
- Efficacy: trial results and how the comparisons are made
- Mechanistic and pharmacologic distinctions relevant to comparisons
- Safety, tolerability, and body-composition signals in the reviewed literature
- Ongoing development and what future evidence could provide
- Reported study-design details from cited sources
- Limitations and research gaps
- Documentation checklist
- Related research supplies
- More Retatrutide research
- Sources and references
Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.
This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.
Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.
This deep dive summarizes what the reviewed clinical and review literature actually compares between retatrutide (a GIP/GLP-1/glucagon triple agonist) and tirzepatide (a GIP/GLP-1 dual agonist), emphasizing which comparisons are direct (head-to-head) versus indirect (cross-trial), and highlighting key efficacy, safety, mechanism, and development-stage data from the reviewed sources.
What the reviewed evidence directly compares
No direct head-to-head randomized controlled trials comparing retatrutide and tirzepatide were available in the reviewed sources; available comparisons are therefore indirect cross-trial or class-level syntheses. [S2]
Efficacy: trial results and how the comparisons are made
Retatrutide (LY3437943) was evaluated in a phase 2, double-blind, randomized, placebo-controlled trial in adults with obesity; dose groups (1 mg, 4 mg, 8 mg, 12 mg once weekly) showed dose-dependent percent reductions in body weight, with least-squares mean percent changes at 48 weeks of −8.7% (1 mg), −17.1% (4 mg combined), −22.8% (8 mg combined), and −24.2% (12 mg) versus −2.1% for placebo in that trial. [S3]
A systematic review of randomized trials across multiple GLP-1 receptor agonists and co-agonists reported tirzepatide (15 mg once weekly) producing up to 17.8% weight loss after 72 weeks, and retatrutide (12 mg once weekly) producing up to 22.1% weight loss after 48 weeks; the review noted heterogeneity across trials and that no head-to-head RCTs were available for direct comparison. [S2]
Phase 2 and phase 3 trial evidence for emerging incretin-based agents shows a range of mean percent weight loss across agents and doses, with completed phase 2 trials on incretin-based therapies reporting mean percent weight loss across studies of approximately 7.4% to 24.2%. [S4]
Mechanistic and pharmacologic distinctions relevant to comparisons
Retatrutide is described in the reviewed sources as a triple receptor agonist that activates GIP, GLP-1, and glucagon receptors; tirzepatide is characterized as a dual GIP–GLP-1 receptor co-agonist. These distinct receptor-targeting profiles underpin mechanistic reasons why efficacy and safety profiles may differ, but the reviewed sources do not provide head-to-head mechanistic comparisons in humans. [S3] [S8] [S5]
Safety, tolerability, and body-composition signals in the reviewed literature
Across the reviewed evidence, gastrointestinal adverse events are the most commonly reported safety signal for retatrutide and for GLP-1–based and co-agonist therapies generally; in the retatrutide phase 2 trial these events were dose-related and mostly mild-to-moderate, and dose-dependent increases in heart rate were reported that peaked around 24 weeks and declined thereafter. [S3] [S2]
Reviews of incretin-based weight-loss therapies note substantial loss of lean mass accompanying large weight reductions (with estimates cited around ∼10% lean mass loss or ∼6 kg in some summaries) and emphasize the potential clinical importance of preserving muscle and bone during pharmacologic weight loss. [S1] [S6]
Ongoing development and what future evidence could provide
Retatrutide is being advanced in a large Phase 3 development program (the TRIUMPH trials) that will evaluate weekly subcutaneous retatrutide compared with placebo across weight-management and adiposity-related complication cohorts; these ongoing registrational trials (planned enrollment >5800) are intended to provide longer-term efficacy and safety data that will be important for more robust cross-agent comparisons. [S7] [S4]
Reported study-design details from cited sources
The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.
| Source | Study Type | Model / Subject | Amount Reported | Route Reported | Frequency | Duration | Notes |
|---|---|---|---|---|---|---|---|
| [S3] | Phase II randomized, double-blind, placebo-controlled trial | Adults with BMI ≥30 or BMI 27– | Least-squares mean percent change in body weight at 24 weeks: −7.2% (1 mg), −12.9% (combined 4 mg), −17.3% (combined 8 mg), −17.5% (12 mg) vs −1.6% placebo. At 48 weeks: −8.7% (1 mg), −17.1% (combined 4 mg), −22.8% (combined 8 mg), −24.2% (12 mg) vs −2.1% placebo. | subcutaneous | once weekly | 48 weeks (primary end point at 24 weeks also reported) | Retatrutide doses evaluated included 1 mg, 4 mg (with different starting doses), 8 mg (with different starting doses), and 12 mg (with initial dose titration in some groups). Adverse events were dose-related and gastrointestinal in nature; heart-rate increases peaked at 24 weeks and declined thereafter. |
| [S2] | Systematic review of randomized controlled trials | Adults with overweight or obesity without diabetes (RCT participants synthesized in review) | Tirzepatide (15 mg once weekly): up to 17.8% weight loss after 72 weeks. Retatrutide (12 mg once weekly): up to 22.1% weight loss after 48 weeks. | once weekly (reported for tirzepatide and retatrutide in review summaries) | once weekly | Trials included in review ranged 16–104 weeks (median 43 weeks); specific reported timepoints: tirzepatide effect cited at 72 weeks, retatrutide effect cited at 48 weeks | No head-to-head RCTs available; heterogeneity across trials prevented meta-analysis. Safety outcomes summarized class-wide included frequent gastrointestinal adverse events. |
| [S6] | Narrative review | Adults with overweight and obesity (narrative/review context) | ∼15–24% weight loss reported for incretin-based agents in adult trials; lean-mass loss estimated around ∼10% or ∼6 kg in summaries. | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | Discusses class-level effects of incretin-based therapies and recommends consideration of resistance exercise to preserve lean mass; cites lean-mass losses associated with large pharmacologic weight loss. |
| [S7] | Phase 3 registrational clinical-trial program (protocol paper) | Adults with obesity (TRIUMPH registrational program includes subcohorts for OSA and knee OA and a CVD population) | not reported in the reviewed source | subcutaneous | once weekly | not reported in the reviewed source | TRIUMPH consists of four randomized, double-blind, placebo-controlled Phase 3 trials evaluating weekly subcutaneous retatrutide with nested OSA and OA protocols; planned enrollment exceeds 5800 participants and trials will evaluate percent change in body weight and disease-specific endpoints. |
Limitations and research gaps
- No direct head-to-head randomized trials comparing retatrutide and tirzepatide are present in the reviewed sources; available comparisons are indirect and cross-trial (S2).
- Reported percent-weight-loss outcomes arise from different trials, doses, and timepoints (for example, retatrutide 12 mg at 48 weeks vs tirzepatide 15 mg at 72 weeks in the systematic review), limiting certainty in cross-agent comparisons (S2, S3).
- Long-term effects on clinical outcomes (cardiorenal events, mortality), body composition preservation, and outcomes in underrepresented populations are not established in the reviewed excerpts and are noted as gaps (S4, S1).
- Class-level safety signals (gastrointestinal adverse events, and reported heart-rate changes with some regimens) are described, but differential tolerability between retatrutide and tirzepatide in head-to-head settings is not reported in the reviewed sources (S3, S2).
Documentation checklist
- Align percent-weight-loss numbers by dose and trial timepoint before comparing.
- Distinguish trial populations (with vs without diabetes, BMI entry criteria) when interpreting results.
- Cite the primary trial report for retatrutide (Phase 2 NEJM) when quoting its dose–response results.
- Flag that no direct head-to-head randomized trial between retatrutide and tirzepatide is reported in the reviewed sources.
- Note class-wide safety signals (gastrointestinal events, and reported heart-rate changes) from trials and systematic reviews.
Related research supplies
- Temperature-controlled storage log template for investigational biologics
- Clinical trial protocol version control checklist
- Study drug accountability ledger template
- Adverse event reporting form template (investigator site)
Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.
Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.
Batch and inventory labeling
Phomemo M110 Label and Barcode Printer
A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.
Label-printer refill
Phomemo M110 White Replacement Labels
White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.
Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.
Research Supply Note: SourcePoint Research currently lists SPR-3RT for research-use-only sourcing. Review current availability and the exact batch documentation at SourcePointResearch.com. This article does not independently certify a SourcePoint batch. Peptide Bio Index is affiliated with SourcePoint Research.
Sources and references
- [S1] Stefanakis K, Kokkorakis M, Mantzoros CS. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.. Metabolism: clinical and experimental. 2024. PMID: 39481534. DOI: 10.1016/j.metabol.2024.156057
- [S2] Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.. Annals of internal medicine. 2025. PMID: 39761578. DOI: 10.7326/ANNALS-24-01590
- [S3] Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.. The New England journal of medicine. 2023. PMID: 37366315. DOI: 10.1056/NEJMoa2301972
- [S4] Kokkorakis M, Chakhtoura M, Rhayem C, Al Rifai J, Ghezzawi M, Valenzuela-Vallejo L. Emerging pharmacotherapies for obesity: A systematic review.. Pharmacological reviews. 2025. PMID: 39952695. DOI: 10.1124/pharmrev.123.001045
- [S5] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy.. Biomolecules. 2025. PMID: 40563436. DOI: 10.3390/biom15060796
- [S6] Locatelli JC, Costa JG, Haynes A, Naylor LH, Fegan PG, Yeap BB. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?. Diabetes care. 2024. PMID: 38687506. DOI: 10.2337/dci23-0100
- [S7] Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.. Diabetes, obesity & metabolism. 2026. PMID: 41090431. DOI: 10.1111/dom.70209
- [S8] Drucker DJ. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.. Diabetes care. 2024. PMID: 38843460. DOI: 10.2337/dci24-0003
Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.